{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:07:40Z","timestamp":1791594460549,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jaclp.2021.07.013","type":"journal-article","created":{"date-parts":[[2021,8,8]],"date-time":"2021-08-08T05:11:35Z","timestamp":1628399495000},"page":"634-644","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8183","authenticated-orcid":false,"given":"Tessa","family":"Manning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bartow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dunlap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kiehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Kneale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaclp.2021.07.013_bib1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1756285610361795","article-title":"Reversible cerebral vasoconstriction syndrome: an under-recognized clinical emergency","volume":"3","author":"Chen","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jaclp.2021.07.013_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7326\/0003-4819-146-1-200701020-00007","article-title":"Narrative review: reversible cerebral vasoconstriction syndromes","volume":"146","author":"Calabrese","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaclp.2021.07.013_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11940-017-0460-7","article-title":"Reversible cerebral vasoconstriction syndrome: Recognition and treatment","volume":"19","author":"Cappelen-Smith","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib4","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/head.12797","article-title":"The Typical thunderclap headache of reversible cerebral vasoconstriction syndrome and its various triggers","volume":"56","author":"Ducros","year":"2016","journal-title":"Headache"},{"key":"10.1016\/j.jaclp.2021.07.013_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11916-020-00908-1","article-title":"Narrative review: headaches after reversible cerebral vasoconstriction syndrome","volume":"24","author":"Ling","year":"2020","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.jaclp.2021.07.013_bib6","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1161\/STROKEAHA.119.024416","article-title":"Reversible cerebral vasoconstriction syndrome","volume":"50","author":"Burton","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.jaclp.2021.07.013_bib7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1941874420953051","article-title":"Illicit drugs and reversible cerebral vasoconstriction syndrome","volume":"11","author":"Short","year":"2021","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jaclp.2021.07.013_bib8","first-page":"32","article-title":"The Epidemiology of reversible cerebral vasoconstriction syndrome in patients at a Colorado Comprehensive stroke center","volume":"10","author":"Jensen","year":"2018","journal-title":"J\u00a0Vasc Interv Neurol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/archneurol.2011.68","article-title":"Reversible cerebral vasoconstriction syndromes: analysis of 139 cases","volume":"68","author":"Singhal","year":"2011","journal-title":"Arch Neurol"},{"issue":"Pt 12","key":"10.1016\/j.jaclp.2021.07.013_bib10","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1093\/brain\/awm256","article-title":"The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients","volume":"130","author":"Ducros","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.jaclp.2021.07.013_bib11","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S1474-4422(12)70135-7","article-title":"Reversible cerebral vasoconstriction syndrome","volume":"11","author":"Ducros","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib12","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1212\/WNL.0000000000006917","article-title":"RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome","volume":"92","author":"Rocha","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jaclp.2021.07.013_bib13","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.21951","article-title":"Magnetic resonance angiography in reversible cerebral vasoconstriction syndromes","volume":"67","author":"Chen","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1212\/WNL.0000000000003510","article-title":"Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome","volume":"88","author":"Singhal","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jaclp.2021.07.013_bib15","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1161\/STROKEAHA.119.027703","article-title":"Long-term outcomes after reversible cerebral vasoconstriction syndrome","volume":"51","author":"Boitet","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jaclp.2021.07.013_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/0333102415591507","article-title":"Long-term outcomes after reversible cerebral vasoconstriction syndrome","volume":"36","author":"John","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.jaclp.2021.07.013_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pharmthera.2010.08.004","article-title":"Contribution of gene-modified mice and rats to our understanding of the cardiovascular pharmacology of serotonin","volume":"128","author":"Monassier","year":"2010","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jaclp.2021.07.013_bib18","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S0021-9258(18)57137-4","article-title":"Serum vasoconstrictor (serotonin)","volume":"176","author":"Rapport","year":"1948","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaclp.2021.07.013_bib19","first-page":"116","article-title":"Platelets and 5-hydroxytryptamine","author":"Stacey","year":"1957","journal-title":"Lond Symp"},{"key":"10.1016\/j.jaclp.2021.07.013_bib20","first-page":"425","article-title":"Inhibition and reversal of serotonin-induced cerebral vasospasm","volume":"13","author":"Karlsberg","year":"1962","journal-title":"Surg Forum"},{"key":"10.1016\/j.jaclp.2021.07.013_bib21","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/head.12202","article-title":"Catastrophic reversible cerebral vasoconstriction syndrome associated with serotonin syndrome","volume":"53","author":"John","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.jaclp.2021.07.013_bib22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10194-009-0117-3","article-title":"Reversible cerebral vasoconstriction syndrome: case report","volume":"10","author":"Oz","year":"2009","journal-title":"J\u00a0Headache Pain"},{"key":"10.1016\/j.jaclp.2021.07.013_bib23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/WNL.58.1.130","article-title":"Cerebral vasoconstriction and stroke after use of serotonergic drugs","volume":"58","author":"Singhal","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.jaclp.2021.07.013_bib24","article-title":"Reversible cerebral vasoconstriction syndrome and monoamine oxidase inhibitors","volume":"18","author":"Durmu\u015f","year":"2016","journal-title":"Prim Care Companion CNS Disord"},{"key":"10.1016\/j.jaclp.2021.07.013_bib25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1212\/01.wnl.0000223648.76430.27","article-title":"Diffuse cerebral vasoconstriction (Call-Fleming syndrome) and stroke associated with antidepressants","volume":"67","author":"Noskin","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.jaclp.2021.07.013_bib26","doi-asserted-by":"crossref","first-page":"e258","DOI":"10.1097\/MJT.0000000000001082","article-title":"Vortioxetine-related Call-Fleming syndrome","volume":"28","author":"Moodliar","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.jaclp.2021.07.013_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009701","article-title":"The reversible cerebral vasoconstriction syndrome in association with venlafaxine and methenamine","volume":"2013","author":"Davies","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaclp.2021.07.013_bib28","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1002\/ccr3.1090","article-title":"A\u00a031-year-old with idiopathic reversible cerebral vasoconstriction syndrome","volume":"5","author":"Qureshi","year":"2017","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jaclp.2021.07.013_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/1941874413518639","article-title":"Reversible cerebral vasoconstriction syndrome with involvement of external carotid artery branches","volume":"4","author":"Shaik","year":"2014","journal-title":"Neurohospitalist"},{"key":"10.1016\/j.jaclp.2021.07.013_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.09.2011.4841","article-title":"A\u00a0reversible cerebral vasoconstriction syndrome","volume":"2012","author":"Ba","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.jaclp.2021.07.013_bib31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.0000000000001473","article-title":"Recurrence of reversible cerebral vasoconstriction syndrome: a long-term follow-up study","volume":"84","author":"Chen","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.jaclp.2021.07.013_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/j.1875-9114.1997.tb03674.x","article-title":"Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects","volume":"17","author":"Stimmel","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jaclp.2021.07.013_bib33","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1345\/aph.1A302","article-title":"Severe serotonin syndrome induced by mirtazapine monotherapy","volume":"36","author":"Hern\u00e1ndez","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"suppl 9","key":"10.1016\/j.jaclp.2021.07.013_bib34","first-page":"5","article-title":"Overview of the mechanism of action of lithium in the brain: fifty-year update","volume":"61","author":"Lenox","year":"2000","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaclp.2021.07.013_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/2045125316656707","article-title":"Safety profile of lamotrigine in overdose","volume":"6","author":"Alabi","year":"2016","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib36","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/JCP.0000000000001121","article-title":"Toxicology Investigators Consortium (ToxIC). Serotonin Toxicity: associated agents and clinical Characteristics","volume":"39","author":"Moss","year":"2019","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"Pt A","key":"10.1016\/j.jaclp.2021.07.013_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2020.11.006","article-title":"Augmentation with atypical antipsychotics for treatment-Resistant depression","volume":"280","author":"Cant\u00f9","year":"2021","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.jaclp.2021.07.013_bib38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/cts.12543","article-title":"Association between serotonin syndrome and Second-generation antipsychotics via pharmacological Target-Adverse event analysis","volume":"11","author":"Racz","year":"2018","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jaclp.2021.07.013_bib39","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system-mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.jaclp.2021.07.013_bib40","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.clineuro.2013.05.022","article-title":"Reversible cerebral vasoconstriction syndrome associated with subarachnoid hemorrhage triggered by hydroxyzine pamoate","volume":"115","author":"Matano","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jaclp.2021.07.013_bib41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.10.007","article-title":"Beta-blockers reduce the risk of early death in ischemic stroke","volume":"252","author":"Dziedzic","year":"2007","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.jaclp.2021.07.013_bib42","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/nu9050429","article-title":"The effects of Magnesium supplementation on subjective anxiety and Stress-A Systematic review","volume":"9","author":"Boyle","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.jaclp.2021.07.013_bib43","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11916-020-00932-1","article-title":"Posterior reversible Encephalopathy syndrome","volume":"25","author":"Gewirtz","year":"2021","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.jaclp.2021.07.013_bib44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.psc.2018.04.009","article-title":"Clinical Usefulness of therapeutic neuromodulation for major depression: a Systematic Meta-review of recent Meta-Analyses","volume":"41","author":"McGirr","year":"2018","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.jaclp.2021.07.013_bib45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1192\/bjp.2018.150","article-title":"Electroconvulsive therapy and later stroke in patients with affective disorders","volume":"214","author":"Rozing","year":"2019","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jaclp.2021.07.013_bib46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000346433","article-title":"Role of repetitive transcranial magnetic stimulation in stroke rehabilitation","volume":"32","author":"Pinter","year":"2013","journal-title":"Front Neurol Neurosci"},{"key":"10.1016\/j.jaclp.2021.07.013_bib47","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/sj.bjp.0704104","article-title":"Pharmacological discrimination between effects of carbamazepine on hippocampal basal, Ca(2+)- and K(+)-evoked serotonin release","volume":"133","author":"Kawata","year":"2001","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaclp.2021.07.013_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A\u00a0summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jaclp.2021.07.013_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.17116\/jnevro202012003229","article-title":"Primenenie askorbata litiia v kachestve tserebroprotektivnogo sredstva na modeli ishemicheskogo insul'ta [Lithium ascorbate as a cerebroprotective agent in a model of ischemic stroke]","volume":"120","author":"Plotnikov","year":"2020","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"10.1016\/j.jaclp.2021.07.013_bib50","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J"}],"container-title":["Journal of the Academy of Consultation-Liaison Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296021001385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667296021001385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T08:43:07Z","timestamp":1757407387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667296021001385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2667296021001385"],"URL":"https:\/\/doi.org\/10.1016\/j.jaclp.2021.07.013","relation":{},"ISSN":["2667-2960"],"issn-type":[{"value":"2667-2960","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversible Cerebral Vasoconstriction Syndrome Associated With Fluoxetine","name":"articletitle","label":"Article Title"},{"value":"Journal of the Academy of Consultation-Liaison Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaclp.2021.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Academy of Consultation-Liaison Psychiatry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}